Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

NCT07330245

Status	RECRUITING
Sponsor	AstraZeneca
Enrollment	218 participants

Key Eligibility Criteria

Inclusion (4)

- Provided informed consent to participate in the study;
- Aged 18 years or older;
- Fulfilled the 2019 EULAR/ACR classification criteria for SLE at the time of study entry;
- Prescribed anifrolumab for SLE treatment for the first time, according to the approved Italian label and reimbursement criteria;

Exclusion (5)

- Patients who are at LLDAS5 at the time of study entry;
- Previous exposure to anifrolumab;
- Documented diagnosis of severe or rapidly progressive Class III or IV glomerulonephritis requiring induction therapy \[mycophenolate mofetil (MMF)/cyclophosphamide (CYC) + high dose steroids\], isolated Class V lupus nephritis, or active severe or unstable neuropsychiatric lupus
- Currently participating in any interventional clinical trial with an investigational product;
- Inability to understand and sign the informed consent and to fill in patient questionnaires

Locations (19 total)

Azienda Ospedaliero-Universitaria di Cagliari Presidio di Monserrato, Monserrato, CA, Italy
Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant'Anna, Cona, Ferrara, Italy
IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy
... and 16 more locations